This program is to develop therapeutic monoclonal antibody against the novel target – —TIM-3 (T-cell immunoglobulin and mucin domain-3). The highlight feature of this program is the powerful therapeutic target – —immune checkpoint TIM-3. With this, we believe this will be a promising program in current bio-pharmaceutical market.
In past few years, immunotherapies have made significant progress on treating malignant tumors. Immune checkpoint blocking drugs are able to pose notable anti-tumor outcomes on receptors like anti-cytotoxic T-lymphocyte-associated protein-4 (anti-CTLA-4) and anti-programmed cell death protein-1 (anti-PD-1). TIM-3 is another key immune checkpoint receptor, and we believe that anti-TIM3 might be next promising therapy for cancer immunotherapy.
Here are highlight features of TIM-3.
Fig.1 Mechanism of action for TIM-3 signaling.1
An increasing number of preclinical studies and clinical studies have indicated that TIM-3 can be a potential target to treat cancer and potentially, has promising anti-tumor efficacy. All the data mentioned below provide athe rationale for therapeutic function of TIM-3 in various cancers. Hence, our program is to develop a therapeutic monoclonal antibody that inhibitsinhibit TIM-3 and suppressessuppress tumor progression in the specific tumor of interests.
• TIM-3 mediates the regulation response of innate and adaptive immunity.
• TIM-3 plays a dual role in proinflammatory and anti-inflammatory tumor microenvironments.
• TIM-3 is upregulated by tumor antigen specific CD8+ T cells and CD8+ tumor infiltrating cells.
Fig.2 TIM-3 is upregulated by tumor antigen specific CD8+ T cells and CD8+ tumor infiltrating cells.5
• Administration of anti-TIM-3 monoclonal antibody enhances cytokine production by improving tumor antigen specific T cells and T cell proliferation.
Fig.3 Administration of anti-TIM-3 monoclonal antibody enhances cytokine production.7
• Increased number of TIM-3 expressed by cancer cell is associated with tumor progression and poor survival times.
TIM-3 is known to be produced by different types of cancer cells, such as sarcoma, gastric, myeloid leukemia, cervical and osteosarcoma etc.
• Preclinical studies show therapeutic potential of anti-TIM-3 and other checkpoint inhibitor combination.
Anti-TIM-3 monoclonal antibodies and their anti-tumor efficacy have been tested in a number of tumor cellsAnti-TIM-3 monoclonal antibody has been tested in many tumor cells and their anti-tumor efficacy. Is supported. Some indications include but are notnot limited to: colon carcinoma, sarcoma, colon adenocarcinoma, prostate tumor, myeloid leukemia, cervical cancer, pulmonary cancer, and osteosarcoma etc. If you are interested in Anti-TIM-3 and its role in other indications, please reach out to our scientists for further communications.
• Several ongoing clinical trials includeis including anti-TIM-3 monoclonal antibodies, such as MBG453 and TSR-022. The efficacy and other data of MBG453 is being evaluated as a single agent and/or in combination with PD-1 monoclonal antibody. TSR-022 is currently evaluated as a single agent but will continue tomove on to test the efficacy and safety readouts in combination with anti-PD-1 mAbs in several tumor types.
We have extensive experience in performing comprehensive program developmentdevelopments and problem-solving. We are committed to reporting progress periodically to our partners and delivering the final complete program to our partners within about 1.5 year, and . Accuratethe exact delivery timeline will be determined case by case. Here is only a very simple draft timeline for quick browsingyour quick glance.
Fig.4 The timeline of Next-IO™ programs.
Creative Biolabs is looking for potential partners to gain collaboration opportunities to develop anti-TIM-3 antibody program. We offer global strategiesprovide global strategic and trusted partnerships with our partners all over the world. Guided by our advanced business strategies, we are dedicated to making drug discovery and development programs the most effective through a collection of efforts. Our rich experience and streamlined management structure enable us to successfully develop the therapeutic product candidate in immuno-oncology field. We believe our Next-IO™ programs will surely be accelerated by combining our skills and expertise.
If you are interested in our programs (not limited to TIM-3, but also other targets you are interested), please feel free to contact us for more details.
For Research Use Only | Not For Clinical Use
Download our brochure